GSK press releases
Follow
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
